Refractory folliculitis decalvans treated with adalimumab: A case series of 23 patients - 19/08/22
Doi : 10.1016/j.jaad.2022.02.044
Matilde Iorizzo, MD, PhD a, ⁎ 
, Michela Starace, MD, PhD b, Sergio Vano-Galvan, MD, PhD c, Bianca Maria Piraccini, MD, PhD b, Pascal Reygagne, MD, PhD d, Lidia Rudnicka, MD, PhD e, Tatiana Silyuk, MD f, Rodney Sinclair, MD, PhD g, Antonella Tosti, MD h
, Michela Starace, MD, PhD b, Sergio Vano-Galvan, MD, PhD c, Bianca Maria Piraccini, MD, PhD b, Pascal Reygagne, MD, PhD d, Lidia Rudnicka, MD, PhD e, Tatiana Silyuk, MD f, Rodney Sinclair, MD, PhD g, Antonella Tosti, MD h a Private Dermatology Practice, Bellinzona/Lugano, Switzerland
b Department of Specialized, Experimental and Diagnostic Medicine, University of Bologna, Italy
c Trichology Unit, Dermatology Department, Ramón y Cajal Hospital, IRYCS, University of Alcala, Madrid, Spain
d Centre Sabouraud, Saint-Louis Hospital, Paris, France
e Department of Dermatology, Medical University of Warsaw, Poland
f Hair Treatment and Transplantation Center, Saint Petersburg, Russia
g Sinclair Dermatology, Melbourne, Australia
h Department of Dermatology, Miller School of Medicine, Miami, Florida
∗Correspondence and reprint requests to: Matilde Iorizzo, MD, PhD, Private Dermatology Practice, Viale Stazione 16 – 6500 Bellinzona, SwitzerlandPrivate Dermatology PracticeViale Stazione 16 – 6500BellinzonaSwitzerland
Key words : adalimumab, biologics, cicatricial alopecia, folliculitis decalvans, hair disorders, hair loss, scarring alopecia, treatment
| Funding sources: None. |
|
| IRB approval status: Approved by the institutional review board of the University Hospital Ramón y Cajal (ACTA 418 - 7/9/21), Madrid, Spain. |
© 2022
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 87 - N° 3
P. 666-669 - septembre 2022 Retour au numéro
Article précédent
- Treatment of lichen planopilaris with baricitinib: A retrospective study
- Anthony Moussa, Bevin Bhoyrul, Leila Asfour, Ahmed Kazmi, Samantha Eisman, Rodney Daniel Sinclair
- Lifestyle risk factor counseling at visits for psoriasis and psoriatic arthritis in the United States
- Matthew T. Taylor, Matthew Keller, John S. Barbieri
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?